Achieve Life Sciences (NASDAQ:ACHV) (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.
Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings. The compound has been used by more than 35,000 patients outside the United States since the 1960s. Achieve is currently conducting a pivotal Phase 3 trial, known as ORCA-2, in the U.S., following receipt of Fast Track designation from the U.S. Food and Drug Administration. Positive outcomes from these studies could form the basis for a New Drug Application submission.
The company holds worldwide rights to cytisinicline, having in-licensed the compound from Sopharma AD. Headquartered in Vancouver, British Columbia, Achieve Life Sciences operates primarily in North America while exploring strategic partnerships for ex-U.S. commercialization. The company’s global strategy leverages a combination of direct development efforts and collaboration agreements to broaden patient access to cytisinicline.
Achieve Life Sciences is led by President and Chief Executive Officer Carole L. Spagnoletti, a seasoned biopharmaceutical executive with over 25 years of experience in clinical development and regulatory affairs. The senior management team comprises professionals with deep expertise in drug development, regulatory strategy, and commercialization planning, all focused on bringing a new smoking cessation therapy to market.
